MCID: NRL004
MIFTS: 56

Neuroleptic Malignant Syndrome

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Neuroleptic Malignant Syndrome

MalaCards integrated aliases for Neuroleptic Malignant Syndrome:

Name: Neuroleptic Malignant Syndrome 12 74 52 53 58 36 54 43 15 17 71

Characteristics:

Orphanet epidemiological data:

58
neuroleptic malignant syndrome
Prevalence: 1-5/10000 (Europe);

Classifications:

Orphanet: 58  
Rare neurological diseases


Summaries for Neuroleptic Malignant Syndrome

KEGG : 36 Neuroleptic malignant syndrome (NMS) is a rare but potentially life-threatening sideeffect to antipsychotic drugs characterized by fever, altered mental status, muscle rigidity, and autonomic dysfunction. NMS is classically associated with the use of high-potency antipsychotics (AP), such as butyrophenones and phenothiazines, but has also been described with newer agents, commonly described as atypical AP (risperidone, olanzapine, quetiapine), other D2-receptor antagonists (metoclopramide), and following withdrawal of anti dopaminergic agents. Although the precise pathophysiologic mechanism underlying NMS remains unknown, a reduction in dopaminergic activity in the brain probably by dopamine D2 receptor blockade in the striatum and hypothalamus is generally assumed as a potential cause. Laboratory findings include elevation of serum creatine phosphokinase (CK), liver enzymes, and leukocitosis. Treatment includes immediately stopping the offending agent and implementing supportive measures, as well as pharmacological interventions in more severe cases.

MalaCards based summary : Neuroleptic Malignant Syndrome is related to acute kidney failure and myoglobinuria. An important gene associated with Neuroleptic Malignant Syndrome is PIK3C2A (Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Alpha), and among its related pathways/superpathways are Beta-Adrenergic Signaling and Circadian entrainment. The drugs Dopamine and Haloperidol have been mentioned in the context of this disorder. Affiliated tissues include brain, kidney and liver, and related phenotypes are fever and hyperhidrosis

Disease Ontology : 12 A nervous system disease that is characterized by hyperthermia, muscular rigidity, autonomic dysfunction and altered consciousness and is associated with administration of antipsychotic and other central dopaminergic blockers.

NIH Rare Diseases : 52 Neuroleptic malignant syndrome is a rare neurological condition that is caused by an adverse reaction to neuroleptic (tranquilizer) or antipsychotic drugs. These drugs are commonly prescribed for the treatment of schizophrenia and other neurological, mental, or emotional disorders. Affected people may experience high fever, muscle stiffness, sweating, unstable blood pressure, altered mental status, and autonomic dysfunction . In most cases, the condition develops within the first 2 weeks of treatment with the drug; however, it may develop any time during the therapy period. The exact underlying cause of neuroleptic malignant syndrome is unknown. In some cases, more than one family member can be affected which suggests there may be a genetic component . Upon diagnosis of the condition, the neuroleptic or antipsychotic drug is generally discontinued under a physician's supervision. Medications and/or other interventions may also be recommended to manage symptoms.

NINDS : 53 Neuroleptic malignant syndrome is a life-threatening, neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic drugs. Symptoms include high fever, sweating, unstable blood pressure, stupor, muscular rigidity, and autonomic dysfunction. In most cases, the disorder develops within the first 2 weeks of treatment with the drug; however, the disorder may develop any time during the therapy period. The syndrome can also occur in people taking anti-Parkinsonism drugs known as dopaminergics if those drugs are discontinued abruptly.

Wikipedia : 74 Neuroleptic malignant syndrome (NMS) is a life-threatening reaction that can occur in response to... more...

Related Diseases for Neuroleptic Malignant Syndrome

Diseases related to Neuroleptic Malignant Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 328)
# Related Disease Score Top Affiliating Genes
1 acute kidney failure 31.0 PIK3C2A MB GPT
2 myoglobinuria 30.8 PIK3C2A MB GPT
3 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 30.8 PIK3C2A MB CHKB CHKA
4 disseminated intravascular coagulation 30.8 PIK3C2A MB GPT
5 serotonin syndrome 30.7 HTR3A HTR2A HTR1A CYP2D6
6 malignant hyperthermia 30.5 RYR3 RYR1 PIK3C2A MB GPT
7 withdrawal disorder 30.5 HTR1A DRD2 DRD1
8 galactorrhea 30.4 DRD2 CYP2D6
9 early-onset schizophrenia 30.1 DRD2 DRD1
10 schizoaffective disorder 30.1 HTR2A HTR1A DRD3 DRD2
11 dementia 30.1 NHLRC1 HTR2A HTR1A DRD2 CYP2D6
12 tardive dyskinesia 30.0 HTR2A DRD3 DRD2 CYP2D6
13 sleep disorder 29.9 HTR2A HTR1A DRD2
14 pain agnosia 29.9 HTR3A HTR1A CYP2D6
15 creatine phosphokinase, elevated serum 29.8 PIK3C2A MB CHKB
16 endogenous depression 29.8 HTR3A HTR2A HTR1A
17 compartment syndrome 29.7 PIK3C2A MB GPT CHKB
18 amnestic disorder 29.6 HTR3A HTR1A DRD2 DRD1
19 movement disease 29.6 DRD3 DRD2 DRD1 CYP2D6
20 generalized anxiety disorder 29.4 HTR3A HTR2A HTR1A DRD2 CYP2D6
21 diarrhea 29.3 HTR3A HTR1A GPT CYP2D6
22 oculogyric crisis 29.2 DRD3 DRD2 DRD1
23 choreatic disease 29.2 DRD3 DRD2 DRD1
24 cocaine abuse 29.1 HTR3A DRD3 DRD2 DRD1
25 dystonia 29.1 RYR1 HTR2A DRD3 DRD2 DRD1 CYP2D6
26 bipolar disorder 29.0 HTR3A HTR2A HTR1A DRD3 DRD2 DRD1
27 bipolar i disorder 29.0 HTR2A HTR1A DRD3 DRD2 DRD1
28 schizophreniform disorder 28.9 HTR2A DRD3 DRD2 DRD1
29 gastroparesis 28.8 HTR3A DRD3 DRD2 DRD1 CYP2D6
30 mood disorder 28.6 HTR3A HTR2A HTR1A DRD3 DRD2 DRD1
31 myocardial infarction 28.6 PIK3C2A MB HTR3A HTR2A GPT CHKA
32 tic disorder 28.6 HTR2A HTR1A DRD3 DRD2 DRD1
33 parkinson disease, late-onset 28.5 HTR3A HTR2A HTR1A DRD3 DRD2 DRD1
34 pervasive developmental disorder 28.5 HTR2A HTR1A DRD3 DRD2 DRD1
35 muscular dystrophy 28.4 RYR1 PIK3C2A MB GPT CHKB CHKA
36 anxiety 28.4 HTR3A HTR2A HTR1A DRD3 DRD2 CYP2D6
37 autism 28.4 HTR3A HTR2A HTR1A DRD3 DRD2 DRD1
38 psychotic disorder 28.4 HTR3A HTR2A HTR1A DRD3 DRD2 DRD1
39 myopathy 28.3 RYR3 RYR1 PIK3C2A MB GPT CHKB
40 gilles de la tourette syndrome 28.1 HTR3A HTR2A HTR1A DRD3 DRD2 DRD1
41 panic disorder 28.1 HTR3A HTR2A HTR1A DRD3 DRD2 DRD1
42 mental depression 28.1 HTR3A HTR2A HTR1A DRD3 DRD2 DRD1
43 obsessive-compulsive disorder 28.1 HTR3A HTR2A HTR1A DRD3 DRD2 DRD1
44 major depressive disorder 28.1 HTR3A HTR2A HTR1A DRD3 DRD2 DRD1
45 schizophrenia 28.0 HTR3A HTR2A HTR1A DRD3 DRD2 DRD1
46 attention deficit-hyperactivity disorder 27.9 HTR2A HTR1A DRD3 DRD2 DRD1 CYP2D6
47 substance abuse 27.8 HTR2A HTR1A GPT DRD3 DRD2 DRD1
48 alcohol use disorder 27.6 HTR3A HTR2A HTR1A GPT DRD3 DRD2
49 alzheimer disease 27.5 RYR3 HTR2A HTR1A DRD3 DRD2 DRD1
50 alcohol dependence 27.5 HTR3A HTR2A HTR1A GPT DRD3 DRD2

Graphical network of the top 20 diseases related to Neuroleptic Malignant Syndrome:



Diseases related to Neuroleptic Malignant Syndrome

Symptoms & Phenotypes for Neuroleptic Malignant Syndrome

Human phenotypes related to Neuroleptic Malignant Syndrome:

58 31 (show top 50) (show all 55)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
2 hyperhidrosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0000975
3 extrapyramidal muscular rigidity 58 31 hallmark (90%) Very frequent (99-80%) HP:0007076
4 mutism 58 31 hallmark (90%) Very frequent (99-80%) HP:0002300
5 abnormal autonomic nervous system physiology 58 31 hallmark (90%) Very frequent (99-80%) HP:0012332
6 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
7 dysphagia 58 31 frequent (33%) Frequent (79-30%) HP:0002015
8 elevated serum creatine kinase 58 31 frequent (33%) Frequent (79-30%) HP:0003236
9 tremor 58 31 frequent (33%) Frequent (79-30%) HP:0001337
10 metabolic acidosis 58 31 frequent (33%) Frequent (79-30%) HP:0001942
11 tachycardia 58 31 frequent (33%) Frequent (79-30%) HP:0001649
12 muscle spasm 58 31 frequent (33%) Frequent (79-30%) HP:0003394
13 leukocytosis 58 31 frequent (33%) Frequent (79-30%) HP:0001974
14 drooling 58 31 frequent (33%) Frequent (79-30%) HP:0002307
15 proteinuria 58 31 occasional (7.5%) Occasional (29-5%) HP:0000093
16 dehydration 58 31 occasional (7.5%) Occasional (29-5%) HP:0001944
17 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
18 hyperuricemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002149
19 anxiety 58 31 occasional (7.5%) Occasional (29-5%) HP:0000739
20 elevated hepatic transaminase 58 31 occasional (7.5%) Occasional (29-5%) HP:0002910
21 hyponatremia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002902
22 hypocalcemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002901
23 hypertensive crisis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100735
24 chorea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002072
25 pulmonary embolism 58 31 occasional (7.5%) Occasional (29-5%) HP:0002204
26 hyperkalemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002153
27 encephalopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001298
28 hypotension 58 31 occasional (7.5%) Occasional (29-5%) HP:0002615
29 aspiration pneumonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011951
30 coma 58 31 occasional (7.5%) Occasional (29-5%) HP:0001259
31 urinary incontinence 58 31 occasional (7.5%) Occasional (29-5%) HP:0000020
32 acute kidney injury 58 31 occasional (7.5%) Occasional (29-5%) HP:0001919
33 hyperphosphatemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002905
34 hypomagnesemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002917
35 thrombocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001894
36 agitation 58 31 occasional (7.5%) Occasional (29-5%) HP:0000713
37 elevated alkaline phosphatase 58 31 occasional (7.5%) Occasional (29-5%) HP:0003155
38 nausea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002018
39 rhabdomyolysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0003201
40 hypernatremia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003228
41 oculogyric crisis 58 31 occasional (7.5%) Occasional (29-5%) HP:0010553
42 myoglobinuria 58 31 occasional (7.5%) Occasional (29-5%) HP:0002913
43 nasogastric tube feeding 58 31 occasional (7.5%) Occasional (29-5%) HP:0040288
44 rigors 58 31 occasional (7.5%) Occasional (29-5%) HP:0025145
45 delirium 58 31 occasional (7.5%) Occasional (29-5%) HP:0031258
46 increased lactate dehydrogenase level 31 occasional (7.5%) HP:0025435
47 thrombocytopenia 58 31 very rare (1%) Very rare (<4-1%) HP:0001873
48 sepsis 58 31 very rare (1%) Very rare (<4-1%) HP:0100806
49 hypothermia 58 31 very rare (1%) Very rare (<4-1%) HP:0002045
50 bradycardia 58 31 very rare (1%) Very rare (<4-1%) HP:0001662

GenomeRNAi Phenotypes related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection GR00234-A-1 8.8 CHKA CHKB PIK3C2A

MGI Mouse Phenotypes related to Neuroleptic Malignant Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.85 CHKB DRD1 DRD2 DRD3 HTR1A HTR2A
2 homeostasis/metabolism MP:0005376 9.7 CHKA CHKB DRD1 DRD2 DRD3 HTR1A
3 muscle MP:0005369 9.28 CHKB DRD1 DRD2 HTR2A HTR3A MB

Drugs & Therapeutics for Neuroleptic Malignant Syndrome

Drugs for Neuroleptic Malignant Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
2
Haloperidol Approved Phase 3 52-86-8 3559
3
Dantrolene Approved, Investigational Phase 2, Phase 3 7261-97-4 6914273 2952
4 Antipsychotic Agents Phase 3
5 Gastrointestinal Agents Phase 3
6 Dopamine Agents Phase 3
7 Neurotransmitter Agents Phase 3
8 Dopamine Antagonists Phase 3
9 Antiemetics Phase 3
10 Psychotropic Drugs Phase 3
11 Haloperidol decanoate Phase 3
12 Antidepressive Agents Phase 3
13 Quetiapine Fumarate Phase 3 111974-72-2
14
Octreotide Approved, Investigational Phase 1, Phase 2 83150-76-9 383414 6400441
15
Prochlorperazine Approved, Vet_approved Phase 1, Phase 2 58-38-8, 1984-02-6 4917
16
Dexmedetomidine Approved, Vet_approved Phase 2 113775-47-6 5311068 68602
17 Antineoplastic Agents, Hormonal Phase 1, Phase 2
18 Adrenergic alpha-Agonists Phase 2
19 Hypnotics and Sedatives Phase 2
20 Analgesics, Non-Narcotic Phase 2
21 Adrenergic Agents Phase 2
22 Adrenergic Agonists Phase 2
23 Analgesics Phase 2
24
Risperidone Approved, Investigational 106266-06-2 5073
25
Acetaminophen Approved 103-90-2 1983
26
Ibuprofen Approved 15687-27-1 3672
27
Creatine Approved, Investigational, Nutraceutical 57-00-1 586
28 Clofibric Acid 882-09-7
29 Hydroxymethylglutaryl-CoA Reductase Inhibitors
30 Antipyretics
31 Cyclooxygenase Inhibitors
32 Anti-Inflammatory Agents
33 Antirheumatic Agents
34 Anti-Inflammatory Agents, Non-Steroidal
35
Serotonin Investigational, Nutraceutical 50-67-9 5202

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Randomized Controlled Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium : The Haloquet Trial Completed NCT01811459 Phase 3 Quetiapine;Haloperidol;Placebo
2 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate
3 Dantrolene as a Treatment for Hyperthermia in Patients After Subarachnoidal Hemorrhage Terminated NCT00796900 Phase 2, Phase 3 Dantrolene;Placebo
4 Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache Unknown status NCT00274170 Phase 1, Phase 2 Octreotide
5 Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia: a Randomized, Controlled, Double Blind, Two-armed Clinical Trial Completed NCT01176721 Phase 2
6 A Randomised Open Label Pilot Study of the Efficacy of Dexmedetomidine and Haloperidol in Ventilated Patients With ICU-associated Agitation and Delirium Completed NCT00505804 Phase 2 dexmedetomidine;haloperidol
7 Rhabdomyolysis - A Retrospective Study in Hospitalized Patients Unknown status NCT01022450
8 Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva Completed NCT00395499 Risperidone
9 Effects of Preemptive Intravenous Paracetamol and Ibuprofen on Headache and Myalgia in Patients After Electroconvulsive Therapy Completed NCT03783312 placebo;paracetamol;ibuprofen
10 Multicenter Assessment of Pre-Electroconvulsive Therapy (ECT) Evaluation and ECT Application Recruiting NCT04335916

Search NIH Clinical Center for Neuroleptic Malignant Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


2-Bromoergocryptine Mesylate
Bromocriptine
Dantrolene
Dantrolene Sodium

Cochrane evidence based reviews: neuroleptic malignant syndrome

Genetic Tests for Neuroleptic Malignant Syndrome

Anatomical Context for Neuroleptic Malignant Syndrome

MalaCards organs/tissues related to Neuroleptic Malignant Syndrome:

40
Brain, Kidney, Liver, Heart, Hypothalamus, Testes, Subthalamic Nucleus

Publications for Neuroleptic Malignant Syndrome

Articles related to Neuroleptic Malignant Syndrome:

(show top 50) (show all 2171)
# Title Authors PMID Year
1
[Catatonia in a 14 year-old girl: treatment with clorazepam and carbamazepine, a 10-year follow-up]. 61 54
20159196 2010
2
Neuroleptic malignant syndrome or a statin drug reaction? A case report. 54 61
19952877 2009
3
Neuroleptic malignant syndrome: a review and report of six cases. 54 61
17214072 2006
4
Massive creatine kinase elevations with quetiapine: report of two cases. 61 54
16453254 2006
5
[Importance of creatine kinase psychiatry--truths and myths]. 61 54
16813275 2006
6
CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report. 61 54
16048458 2005
7
Cardiac involvement in malignant syndrome in Parkinson's disease. 61 54
16145285 2005
8
Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. 54 61
12555236 2003
9
High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. 61 54
12006894 2002
10
Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome. 54 61
11579007 2001
11
Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity. 54 61
11204351 2000
12
Psychopharmacology research in the English-speaking Caribbean. 61 54
10820583 2000
13
Severe catatonia and neuroleptic malignant syndrome: report of 3 cases. 54 61
10561954 1999
14
CYP2D6 HhaI genotype and the neuroleptic malignant syndrome. 61 54
9892857 1999
15
Lack of association between neuroleptic malignant syndrome and polymorphisms in the 5-HT1A and 5-HT2A receptor genes. 61 54
9734554 1998
16
Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. 54 61
9804127 1998
17
Neuroleptic malignant syndrome with risperidone. 61 54
9165568 1997
18
The obscure autopsy and neuroleptic malignant syndrome. 61 54
9029927 1997
19
Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B. 61 54
9323326 1997
20
[Neuroleptic malignant syndrome, syndrome malin]. 54 61
8904246 1996
21
The role of creatine kinase in the diagnosis of neuroleptic malignant syndrome. 61 54
8101383 1993
22
[Creatine phosphokinase in a hospitalized psychiatric population]. 54 61
1362345 1992
23
[The relationship between syndrome malin and neuroleptic malignant syndrome, and rhabdomyolysis]. 54 61
1970519 1990
24
Deep brain stimulation as a possible treatment of hyperthermia in patients with serotonin syndrome. 61
32251940 2020
25
Pharmacist-Initiated Management of a Suspected Case of Risperidone-Induced Neuroleptic Malignant Syndrome in an Aged-Care Resident. The Role of Residential Medication Management Reviews in Medication Safety. 61
30428759 2020
26
Valproate and Neuroleptic Malignant Syndrome in an Elderly Patient With Schizoaffective Disorder. 61
32530580 2020
27
Severe Agitation in a Teenager With Spastic Cerebral Palsy: A Clinical Challenge. 61
32384395 2020
28
Neuroleptic malignant syndrome in patients with COVID-19. 61
32473756 2020
29
Neuroleptic malignant syndrome in a COVID-19 patient. 61
32425332 2020
30
Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors. 61
32329312 2020
31
Hypermetabolic Syndrome and Dyskinesia After Neurologic Surgery for Labrune Syndrome: A Case Report. 61
32371820 2020
32
Neuroleptic malignant syndrome in patients with cancer: a systematic review. 61
32414787 2020
33
Coexistence of guanidinoacetate methyltransferase (GAMT) deficiency and neuroleptic malignant syndrome without creatine kinase elevation. 61
32173091 2020
34
Neuroleptic malignant syndrome: A case report. 61
32195874 2020
35
Neuroleptic malignant syndrome: A case report. 61
32195873 2020
36
Lithium induced reversible Splenial lesion in neuroleptic malignant syndrome like symptoms: two case reports. 61
32354328 2020
37
Lamotrigine, quetiapine and aripiprazole-induced neuroleptic malignant syndrome in a patient with renal failure caused by lithium: a case report. 61
32306929 2020
38
Neuroleptic malignant syndrome in an afebrile patient on second generation antipsychotics. 61
32109803 2020
39
Effect of Delirium on Physical Function in Noncardiac Thoracic Surgery Patients. 61
32114617 2020
40
Treatment of the Neuroleptic Malignant Syndrome in International Therapy Guidelines: A Comparative Analysis. 61
31820427 2020
41
Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015. 61
30506147 2020
42
Catatonia revived: a unique syndrome updated. 61
32067538 2020
43
Drug-associated non-pyrogenic hyperthermia: a narrative review. 61
31642960 2020
44
The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review. 61
31653394 2020
45
Lifesaving Electroconvulsive Therapy for a Child With Autism Spectrum Disorder, Severe Self-Injurious Behavior, and Neuroleptic Malignant Syndrome. 61
31764456 2019
46
Electroconvulsive Therapy for Neuroleptic Malignant Syndrome: A Case Series. 61
31764444 2019
47
[Catatonia in clinical reality: underdiagnosed and forgotten]. 61
31828672 2019
48
Aripiprazole Induced Late Neuroleptic Malignant Syndrome. 61
30730330 2019
49
A Look at Genetic Linkage between Clozapine-induced Agranulocytosis, Malignant Hyperthermia, Neuroleptic Malignant Syndrome, and Statin-induced Myopathy. 61
32082940 2019
50
Serum osmolarity and blood viscosity as a potential explanation for the pathophysiology of neuroleptic malignant syndrome. 61
31116616 2019

Variations for Neuroleptic Malignant Syndrome

Expression for Neuroleptic Malignant Syndrome

Search GEO for disease gene expression data for Neuroleptic Malignant Syndrome.

Pathways for Neuroleptic Malignant Syndrome

Pathways related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.5 RYR3 RYR1 DRD3 DRD2 DRD1
2
Show member pathways
12.44 RYR3 RYR1 DRD3 DRD2 DRD1
3
Show member pathways
11.92 RYR3 RYR1 HTR2A DRD1
4 11.77 RYR1 HTR1A CHKA
5 11.55 HTR2A DRD2 DRD1
6 11.52 HTR3A HTR2A HTR1A CYP2D6
7
Show member pathways
11.4 HTR2A HTR1A DRD3 DRD2 DRD1
8 10.88 HTR3A HTR2A HTR1A
9 10.81 DRD2 ANKK1
10
Show member pathways
10.68 HTR3A CYP2D6
11 10.57 RYR3 RYR1
12
Show member pathways
10.29 HTR1A DRD3 DRD2 DRD1

GO Terms for Neuroleptic Malignant Syndrome

Cellular components related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.91 RYR3 RYR1 HTR2A DRD3 DRD2 DRD1
2 integral component of plasma membrane GO:0005887 9.87 RYR1 HTR3A HTR2A HTR1A DRD3 DRD2
3 synapse GO:0045202 9.73 HTR3A HTR2A HTR1A DRD3 DRD2 DRD1
4 glutamatergic synapse GO:0098978 9.55 HTR3A HTR2A DRD3 DRD2 DRD1
5 GABA-ergic synapse GO:0098982 9.54 DRD3 DRD2 DRD1
6 calcium channel complex GO:0034704 9.46 RYR3 RYR1
7 dopaminergic synapse GO:0098691 9.4 DRD3 DRD2
8 integral component of presynaptic membrane GO:0099056 9.26 HTR3A HTR2A DRD2 DRD1
9 integral component of postsynaptic membrane GO:0099055 8.92 HTR3A HTR2A DRD2 DRD1

Biological processes related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.98 HTR2A DRD3 DRD2 DRD1
2 response to ethanol GO:0045471 9.88 HTR3A DRD3 DRD2
3 response to toxic substance GO:0009636 9.85 DRD3 DRD2 CHKA
4 locomotory behavior GO:0007626 9.85 DRD3 DRD2 DRD1
5 cellular calcium ion homeostasis GO:0006874 9.85 RYR3 RYR1 HTR2A DRD3
6 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.82 DRD3 DRD2 DRD1
7 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.81 HTR2A HTR1A DRD1
8 regulation of synaptic vesicle exocytosis GO:2000300 9.8 HTR2A DRD2 DRD1
9 visual learning GO:0008542 9.79 DRD3 DRD2 DRD1
10 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.77 DRD3 DRD2 DRD1
11 response to amphetamine GO:0001975 9.74 DRD3 DRD2 DRD1
12 regulation of dopamine secretion GO:0014059 9.73 HTR2A DRD3 DRD2
13 negative regulation of protein secretion GO:0050709 9.71 DRD3 DRD2
14 arachidonic acid secretion GO:0050482 9.71 DRD3 DRD2
15 temperature homeostasis GO:0001659 9.71 HTR2A DRD2 DRD1
16 negative regulation of adenylate cyclase activity GO:0007194 9.7 DRD3 DRD2
17 negative regulation of voltage-gated calcium channel activity GO:1901386 9.7 DRD3 DRD2
18 behavioral response to ethanol GO:0048149 9.7 DRD3 DRD2
19 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.7 DRD3 DRD2 DRD1
20 behavior GO:0007610 9.69 HTR2A HTR1A
21 phosphatidylethanolamine biosynthetic process GO:0006646 9.69 CHKB CHKA
22 positive regulation of renal sodium excretion GO:0035815 9.69 DRD3 DRD2
23 dopamine receptor signaling pathway GO:0007212 9.69 DRD3 DRD2 DRD1
24 grooming behavior GO:0007625 9.68 DRD2 DRD1
25 G protein-coupled receptor internalization GO:0002031 9.68 DRD3 DRD2
26 striatum development GO:0021756 9.67 DRD2 DRD1
27 regulation of potassium ion transport GO:0043266 9.67 DRD3 DRD2
28 synaptic transmission, dopaminergic GO:0001963 9.67 DRD3 DRD2 DRD1
29 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.66 DRD3 DRD1
30 cellular response to caffeine GO:0071313 9.66 RYR3 RYR1
31 regulation of dopamine metabolic process GO:0042053 9.65 HTR1A DRD1
32 peristalsis GO:0030432 9.65 DRD2 DRD1
33 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.65 DRD3 DRD2
34 negative regulation of cytosolic calcium ion concentration GO:0051481 9.65 RYR3 DRD3 DRD2
35 CDP-choline pathway GO:0006657 9.64 CHKB CHKA
36 cerebral cortex GABAergic interneuron migration GO:0021853 9.63 DRD2 DRD1
37 prepulse inhibition GO:0060134 9.63 DRD3 DRD2 DRD1
38 regulation of neurotransmitter uptake GO:0051580 9.62 DRD3 DRD2
39 release of sequestered calcium ion into cytosol GO:0051209 9.62 RYR3 RYR1 HTR2A DRD2
40 negative regulation of dopamine receptor signaling pathway GO:0060160 9.61 DRD3 DRD2
41 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.61 HTR2A DRD3 DRD2
42 regulation of locomotion involved in locomotory behavior GO:0090325 9.59 DRD3 DRD2
43 acid secretion GO:0046717 9.58 DRD3 DRD2
44 response to histamine GO:0034776 9.58 DRD3 DRD2
45 dopamine metabolic process GO:0042417 9.58 DRD3 DRD2 DRD1
46 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.54 DRD3 DRD2 DRD1
47 response to cocaine GO:0042220 9.46 HTR3A DRD3 DRD2 DRD1
48 serotonin receptor signaling pathway GO:0007210 9.43 HTR3A HTR2A HTR1A
49 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.13 DRD3 DRD2 DRD1
50 behavioral response to cocaine GO:0048148 8.92 HTR2A DRD3 DRD2 DRD1

Molecular functions related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.67 HTR3A HTR2A HTR1A
2 calcium-release channel activity GO:0015278 9.51 RYR3 RYR1
3 adrenergic receptor activity GO:0004935 9.5 DRD3 DRD2 DRD1
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.48 DRD3 DRD2
5 calcium-induced calcium release activity GO:0048763 9.46 RYR3 RYR1
6 ryanodine-sensitive calcium-release channel activity GO:0005219 9.43 RYR3 RYR1
7 dopamine binding GO:0035240 9.43 DRD3 DRD2 DRD1
8 ethanolamine kinase activity GO:0004305 9.4 CHKB CHKA
9 choline kinase activity GO:0004103 9.37 CHKB CHKA
10 serotonin binding GO:0051378 9.33 HTR3A HTR2A HTR1A
11 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD3 DRD2 DRD1
12 drug binding GO:0008144 9.02 HTR2A DRD3 DRD2 CYP2D6 CHKA

Sources for Neuroleptic Malignant Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....